Bionano Genomics has priced a public offering of 5 million common stock shares at $2.00 each, aiming to raise $10 million before expenses, with concurrent offerings of up to 5 million Series E and Series F warrants that could bring an additional $20 million if fully exercised. The proceeds will support working capital and corporate purposes. The offering is expected to close mid-September, subject to conditions. This capital raise occurs amid the company’s ongoing efforts to advance its genomics technologies.